Increased circulating myeloid-derived suppressor cells in vivax malaria and severe falciparum malaria
September 6, 2022
Background: Circulating myeloid-derived-suppressor-cells (MDSC) with immunosuppressive function are increased in human experimental Plasmodium falciparum infection, but have not been studied…
Induction, decay and determinants of functional antibodies following vaccination with the RTS,S malaria vaccine in young children
August 25, 2022
Background RTS,S is the first malaria vaccine recommended for implementation among young children at risk. However, vaccine efficacy is modest…
Comparison of Antibody Responses and Parasite Clearance in Artemisinin Therapeutic Efficacy Studies in the Democratic Republic of Congo and Asia
August 24, 2022
Background Understanding the effect of immunity on Plasmodium falciparum clearance is essential for interpreting therapeutic efficacy studies designed to monitor…
Assessment of IgG3 as a serological exposure marker for Plasmodium vivax in areas with moderate-high malaria transmission intensity
August 9, 2022
A more sensitive surveillance tool is needed to identify Plasmodium vivax infections for treatment and to accelerate malaria elimination efforts….
Pregnancy and Malaria: The perfect storm
July 25, 2022
Purpose of review: Malaria in pregnancy continues to exert a toll on pregnant women and their offspring. Recent findings: The burden of…
Heterogeneity in prevalence of subclinical Plasmodium falciparum and Plasmodium vivax infections but no parasite genomic clustering in the Chittagong Hill Tracts, Bangladesh
July 14, 2022
Background Malaria remains endemic in Bangladesh, with the majority of cases occurring in forested, mountainous region in the Chittagong Hill…
A Multiscale Mathematical Model of Plasmodium Vivax Transmission
July 1, 2022
Malaria is caused by Plasmodium parasites which are transmitted to humans by the bite of an infected Anopheles mosquito. Plasmodium…
Geographical distribution and genetic diversity of Plasmodium vivax reticulocyte binding protein 1a correlates with patient antigenicity
June 23, 2022
Plasmodium vivax is the most widespread cause of human malaria. Recent reports of drug resistant vivax malaria and the challenge of…
Intermittent screening and treatment for malaria complementary to routine immunisation in the first year of life in Papua, Indonesia: a cluster randomised superiority trial
June 8, 2022
Background In Papua (Indonesia), infants with P. falciparum and/or P. vivax malaria are at risk of severe anaemia and death. We hypothesized that in…
Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas – a radomised controlled trial
May 18, 2022
Background Plasmodium vivax forms dormant liver stages that can reactivate weeks or months following an acute infection. Recurrent infections are…